Xeris Biopharma Holdings, Inc. (XERS)
$9.77-4.22%Close
BUYBULL · day 7
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $1.7B
- Beta
- 0.84
- P/E (TTM)
- -100.62
- Short % float
- 4.37%
- Days to cover
- 1.7
- SI change
- -10.6%
- 1W
- -3.36%
- 1M
- +30.44%
- vs SPY 1W
- -2.38%
- vs SPY 1M
- +28.58%
Industry peers
FMP comparable companies · ranked by market cap
- ASNDSELLAscendis Pharma A/S$13.8BRECOVERYQ 35$222.69+1.70%
- CORTBUYCorcept Therapeutics Incorporated$12.8BBULLQ 21$118.54-1.33%
- MBXSELLMBX Biosciences, Inc. Common Stock$2.5BCRISISQ 36$53.25-0.37%
- SEPNSELLSepterna Inc$1.7BRECOVERYQ 26$36.90-0.27%
- ETONSELLEton Pharmaceuticals, Inc.$1.5BRECOVERYQ 33$54.75-0.84%
- GHRSSELLGH Research PLC$1.4BCRISISQ 14$20.45-1.54%
- MNKDSELLMannKind Corporation$1.1BCRISISQ 3$3.42-0.98%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS & VALIDATION
[SCORES & PROFILE]
- FUND
- 45
- VALUE
- 4
- GROWTH
- 51
- GARP
- 59
- TYPE
- Growth Compounder
Composite of Value · Growth · GARP
ROIC-255.8%
REV YoY-
ROE-426.3%
EPS YoY-
ROA-4.2%
GROSS83
OP11
NET-5
[VALUATION]
P/E TTM-100.62
P/E FWD32.12
SECTOR PE20.48
INDUSTRY PE13.99
P/B-173.46
P/FCF-
EV/EBITDA111.79
EV/EBIT-
PEG0.66
FCF YIELD-
RISK
INT COV-
D/E-
ALTMAN Z-
CURR RATIO1.45
ND/EBITDA-
BETA0.84
[BEST COMBO]VALIDATED · V5
ENTER · HOLD · EXIT · WAITOne next-open action from five signal families, published only when the held-out edge survives 20 bps costs.
Today's action with its out-of-fold profit factor, trade count and family votes.
[WHITE ARROW]FULL HISTORY
BUY
Directional consensus stays BUY or SELL until the model reverses; trades fill next session open.
PROFIT FACTOR1.6
TRADES38
[REGIME]FULL HISTORY
BULL
BULL or RECOVERY stays invested; BEAR or CRISIS exits at the next session open.
Profit factor and trade count for holding this symbol only in BULL or RECOVERY.
[EXHAUSTION]NOW
Whether buyers or sellers are stretched today, the latest release and its strength.
Company news
FAQ
- What is LOPJLB’s current signal on XERS?
- LOPJLB’s latest quantitative signal on Xeris Biopharma Holdings, Inc. (XERS) is BUY in a BULL regime. Signals are updated daily.
- What market regime is XERS in?
- Xeris Biopharma Holdings, Inc. (XERS) is currently classified in the BULL HMM market regime on LOPJLB.
- What does Xeris Biopharma Holdings, Inc. (XERS) do?
- Xeris Biopharma Holdings, Inc. operates as a biopharmaceutical company, focusing on the development and commercialization of therapeutic solutions for individuals across the fields of endocrinology, neurology, and gastroenterology. Its current portfolio includes: Gvoke: A ready-to-administer liquid glucagon designed to treat severe hypoglycemia. Keveyis: A therapy addressing hyperkalemic, hypok…